Samla, Samer E.

HRN: 21-27-23  Sex: Male

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
04/16/2022
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
04/16/2022
04/23/2022
IV
500mg
Q8H
Avulse Contaminated Wound
Waiting Final Action 

Indication:  Empiric    Type of Infection:  Skin & Soft Tissue    Compliance to guidelines: Guideline Not Available

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: